Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17; 371(9625):1665-74.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Double-Blind Method
Drug Administration Schedule
Female
Humans
Interleukin-12
Interleukin-23
Keratolytic Agents
Male
Middle Aged
Psoriasis
Severity of Illness Index
Treatment Outcome

authors with profiles

Kenneth Gordon